Drugs / CN401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04880564 | Jul 2021 → Aug 2022 | lymphoma | Curon Biopharmaceutical (Australia) Co Pty Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04880564 ↗ |
| Route | Oral | “CN401- Tablet, Oral” NCT04880564 ↗ |